Dr. Britt Drögemöller received her PhD from Stellenbosch University in South Africa in 2013. She continued her training in pharmacogenomics and precision medicine at the University of British Columbia, where she completed a postdoctoral fellowship at the Canadian Pharmacogenomics Network for Drug Safety. Dr. Drögemöller joined the Department of Biochemistry & Medical Genetics at the University of Manitoba as an Assistant Professor in 2020.
Area of Research: Pharmacogenomics and precision medicine
Dr. Drögemöller’s research utilizes genomic and bioinformatic analyses to identify genetic variants underlying severe adverse drug reactions to therapeutic treatments. Building on this research, Dr. Drögemöller has also been involved in the identification of variants that cause rare and potentially treatable inborn errors of metabolism. Dr. Drögemöller is currently an active member of several international pharmacogenomics initiatives, including the Human, Hereditary and Health in Africa (H3A) Pharmacogenomic Working Group and the Pharmacogene Variation (PharmVar) Consortium. Dr. Drögemöller was also on the founding committee for hackseq - the first genomics hackathon to be held in Canada.
Advances in modern medicine have dramatically improved the treatment of disease. Unfortunately, effective treatments are still lacking for many diseases and existing therapeutic interventions are often limited by severe adverse drug reactions. As genetic variants have been shown to be a key determinant of treatment outcomes, genetic data can be used as a tool predict and prevent adverse events. In line with this, it has been demonstrated that the inclusion of genetic data into drug development pipelines dramatically increases the likelihood of success of therapeutic drugs.
The Drögemöller Lab uses large-scale genomic and computational analyses to guide the development of novel treatment strategies that offer maximum benefit and minimal harm. This research is focused specifically on vulnerable and understudied populations (e.g. pediatric and maternal populations) as therapeutic agents are often not designed and tested with these patients in mind.
Dr. Drögemöller is currently recruiting graduate students and postdoctoral fellows with expertise in genomics, bioinformatics, pharmacogenomics and precision medicine. Interested individuals should send a recent CV, along with a short cover letter explaining why they are interested in joining the lab.
Google scholar; PubMed
Drögemöller B, Wright G, Lo C, Le T, Brooks B, Bhavsar A, Rassekh S, Ross C, Carleton B. Pharmacogenomics of cisplatin-induced ototoxicity: Successes, shortcomings and future avenues of research. Clin Pharmacol Ther. 2019;106:350-9.
Drögemöller B*, Wright G*, Shih J, Aminkeng F, Amstutz U, Hayden M, Ross C, Carleton B; CPNDS Clinical Recommendation Group. CYP2D6 as a treatment decision aid for ER-positive non-metastatic breast cancer patients: a systematic review with accompanying clinical practice guidelines. Breast Cancer Res Treat. 2019;173:521-32.
*Contributed equally to the work
van Kuilenburg A*, Tarailo-Graovac M*, Richmond P*, Drögemöller B, Pouladi M, Leen R, Brand-Arzamendi K, Dobritzsch D, Dolzhenko E, Eberle M, Hayward B, Karbassi F, Jones M, Kobor M, Koster J, Kumari D, Li M, McDonald C, Meijer J, Nguyen C, Rajan-Babu I-S, Scherer S, Sim B, Trost B, Tseng L, Turkenburg M, van Vugt J, Veldink J, Walia J, Wang Y, van Weeghel M, Wright G, Xu X, Yuen R, Zhang J, Ross C, Wasserman W, Geraghty M, Santra S, Wanders R, Wen X-Y, Waterham H, Usdin K, van Karnebeek C. An etiologic repeat expansion in glutaminase deficiency. N Engl J Med. 2019;380:1433-41.
Kowalec K*, Wright G*, Drögemöller B, Aminkeng F, Bhavsar A, Kingwell E, Yoshida E, Traboulsee A, Marrie R, Kremenchutzky M, Campbell T, Duquette P, Chalasani N, Wadelius M, Hallberg P, Xia Z, De Jager P, Ross C, Tremlett H, Carleton B. A novel pharmacogenomic risk locus for interferon-beta induced liver injury in multiple sclerosis. Nat Genet. 2018;50:1081-5.
Drögemöller B, Brooks B, Critchley C, Monzon J, Wright G, Liu G, Renouf D, Kollmannsberger C, Bedard P, Hayden M, Gelmon K, Carleton B, Ross C. Further evidence for the role of ACYP2 and WFS1 pharmacogenomic variants in the development of cisplatin-induced ototoxicity in testicular cancer patients. Clin Cancer Res. 2018;24:1866-71.
Drögemöller B*, Monzon J*, Bhavsar A, Borrie A, Brooks B, Wright G, Liu G, Renouf D, Kollmannsberger C, Bedard P, Aminkeng F, Amstutz U, Hildebrand C, Gunaretnam E, Critchley C, Chen Z, Brunham L, Hayden M, Ross C, Gelmon K, Carleton B. Association between SLC16A5 genetic variation and cisplatin-induced ototoxic effects in adult patients with testicular cancer. JAMA Oncol. 2017;3:1558-62.
*Contributed equally to the work